Houston, Tx., July 29, 2015 - Vyripharm Biopharmaceuticals is pleased to announce a research agreement with MD Anderson Cancer Center, the world’s No. 1 cancer center, to study the effects of medicinal cannabinoids on cancer therapy. The focus of the study is to develop and characterize the cancer therapeutic efficacy of cannabinoid compounds and its derivatives in B-cell lymphomas. The goals of this study are to utilize extracts, synthetics, formulated natural medicinal cannabinoids in combination with traditional cancer therapeutics for targeted therapy in lymphomas.
Elias Jackson Ph.D., Vyripharm’s President of Research and Development commented, “Vyripharm is honored and excited to be working with MD Anderson. We feel this project could potentially usher in a new era in the fight against Cancer”